Potent  in vitro  and  in vivo  effects of polyclonal anti-human-myeloma globulins

Aneta Schieferdecker; Ofer Shoshani; Benedikt Westner; Dov Zipori; Boris Fehse; Nicolaus Kröger; Francis Ayuk

doi:10.18632/oncotarget.11489

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins

Aneta Schieferdecker, Ofer Shoshani, Benedikt Westner, Dov Zipori, Boris Fehse, Nicolaus Kröger and Francis Ayuk _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:67061-67070. https://doi.org/10.18632/oncotarget.11489

Metrics: PDF 2585 views | HTML 3660 views | ?

Abstract

Aneta Schieferdecker1,2, Ofer Shoshani3,4, Benedikt Westner5,6, Dov Zipori3, Boris Fehse1, Nicolaus Kröger1, Francis Ayuk1

1Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

2Current Affiliation: Department of Oncology and Hematology with Section Pneumology, Hubertus Wald Tumorzentrum/ UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

3Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel

4Current Affiliation: San Diego Branch, Ludwig Institute for Cancer Research, La Jolla, CA, USA

5Neovii (formerly Fresenius) Biotech GmbH, Gräfelfing, Germany

6Current Affiliation: Acino AG, Miesbach, Germany

Corresponding to:

Francis Ayuk, email: [email protected]

Keywords: myeloma, anti-human-myeloma globulins, AMG, polyclonal antibodies, ATG

Received: March 25, 2016 Accepted: August 10, 2016 Published: August 22, 2016

ABSTRACT

Introduction: Multiple myeloma is still incurable in most cases. Polyclonal anti T lymphocyte globulins (ATG) have been reported to kill human myeloma cells in vitro and in mouse models.

Methods: Anti-human-myeloma globulins (AMG) were produced by immunizing rabbits with human myeloma cell lines RPMI-8226 (AMG-8226) or KMS-12-BM (AMG-12-BM). Cytotoxicity of the polyclonal antibodies was analyzed in vitro and in a xenograft NOD-SCID mouse model.

Results: Both AMG had stronger cytotoxicity against myeloma cells compared to ATG. In primary T cells, AMG-8226 showed greater complement-dependent cytotoxicity (CDC) than ATG, whereas complement-independent cytotoxicity did not differ. Effects on non-hematopoietic cell lines were also similar. Competitive blocking assays revealed fourfold more antibodies against CD38 in AMG-8226 compared to ATG. Low concentrations of AMG-8226 and ATG increased ADCC. At higher concentrations, ATG inhibited ADCC more potently than AMG-8226. Combinations of ATG and AMG-8226 with melphalan or bortezomib showed additive to synergistic cytotoxicity on myeloma cells. The cytotoxic effects of AMG and ATG were confirmed in the xenograft NOD-SCID mouse model.

Conclusion: Our data show more potent antimyeloma effects of AMG compared to ATG. These results lay the ground for the development of polyclonal antibodies for the treatment of multiple myeloma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11489

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins

Abstract